Day: August 27, 2024

Boussard & Gavaudan Holding Limited (the “Company”) a closed-ended investment company incorporated with limited liability under the laws of Guernsey with registration number 45582 Legal Entity Identifier: 5493002XNM3W9D6DF327 Half-Yearly Financial Report The Company has submitted its half-yearly report and unaudited interim condensed financial statements for the six months ended 30 June 2024 (the “HYFR”) to the National Storage Mechanism and it will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The HYFR is also available for download from the Company’s website, http://www.bgholdingltd.com. For further information please contact: Boussard & Gavaudan Investment Management, LLP Emmanuel Gavaudan   +44 20 3751 5389 JTC Fund Solutions (Guernsey) Limited Secretary +44 (0) 1481 702400 27...

              Boussard & Gavaudan Holding Limited (the “Company”) a closed-ended investment company incorporated with limited liability under the laws of Guernsey with registration number 45582 Legal Entity Identifier: 5493002XNM3W9D6DF327                                Half-Yearly Financial Report On 27 August 2024, the Company’s board of directors resolved to approve the half-yearly report and unaudited interim condensed financial statements of the Company for the six months ended 30 June 2024 (the “HYFR”). The HYFR is available on the Company’s website (www.bgholdingltd.com) and at the registered office of the Company at Ground Floor, Dorey Court, Admiral Park, St Peter Port, Guernsey GY1 2HT. In addition, copies of the HYFR are available upon request free of charge at the address of the Dutch Listing Agent Van Lanschot Kempen...

Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) — Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced the appointment of Mao Zhang as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance. Mr. Mao Zhang is the Founder and Chief Executive Officer of StellarS Capital, a multi-billion-dollar alternative asset management firm established in 2016. He has over 15 years of experience in financial markets including hedge fund and private equity. He began his career with Magnetar Capital in 2007, leading its Asian business. He holds a Bachelor of Science...

Houston, USA (27 August 2024) – TGS, a leading global provider of energy data and intelligence and Petrobras, one of the world’s largest energy companies, announced today the signing of a Memorandum of Understanding (MoU) to collaborate on scientific research and technological development activities in Brazil. This MoU marks the beginning of a strategic partnership between the two companies, with the goal of leveraging the expertise and resources of both parties to drive innovation in the energy sector. The collaboration will focus on developing new technologies and conducting advanced research to increase efficiency and sustainability in oil and gas exploration and production. Additionally, it will drive innovation in renewable energy technologies and carbon capture solutions. Partnership Objectives: Technological Development: Petrobras...

In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic sales outlook from 5-7% to 7-8% and increases adjusted EBITDA-margin expectations from 35-36% to 35.5-36.5%. COPENHAGEN, Denmark – August 27, 2024. Novonesis delivers 7% organic sales growth with an adjusted EBITDA margin at 35.3% in the first half of the 2024 financial year, and now expects an organic sales growth of 7-8% with an adjusted EBITDA margin of 35.5%-36.5%. The sales growth is broad-based and driven by both Food & Health Biosolutions and Planetary Health Biosolutions. “We continue to execute strongly across the business, and I am very pleased with the first half-year performance delivering a broad-based 7% organic sales...